The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy?
Lemanske
Robert F
RF
Busse
William W
WW
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D000420:Albuterol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000592:standards / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D054796:Drug Dosage Calculations; D004348:Drug Labeling; D006801:Humans; D012307:Risk Factors; D000068299:Salmeterol Xinafoate; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D000068299:Salmeterol Xinafoate; D000420:Albuterol